Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00410761
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-10-02
First Post:
2006-12-06
Brief Title:
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
An International Phase III Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 ZACTIMATM Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients treated with ZD6474 react to the drug what happens to ZD6474 in the human body about the side effects of ZD6474 and if ZD6474 can decrease or prevent the growth of tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LPS14811 | OTHER | Sanofi | None |
| 2005-005077-29 | EUDRACT_NUMBER | None | None |